|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Arnold M, Sierra MS, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global patterns and trends in
colorectal cancer incidence and mortality. Gut. 66:683–691.
2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Zhu J, Tan Z, Hollis-Hansen K, Zhang Y, Yu
C and Li Y: Epidemiological trends in colorectal cancer in China:
An ecological study. Dig Dis Sci. 62:235–243. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Rodriguez-Salas N, Dominguez G, Barderas
R, Mendiola M, García-Albéniz X, Maurel J and Batlle JF: Clinical
relevance of colorectal cancer molecular subtypes. Crit Rev Oncol
Hematol. 109:9–19. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Stoffel EM and Yurgelun MB: Genetic
predisposition to colorectal cancer: Implications for treatment and
prevention. Semin Oncol. 43:536–542. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Carethers JM and Jung BH: Genetics and
genetic biomarkers in sporadic colorectal cancer. Gastroenterology.
149:1177–1190 e1173. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Bignucolo A, De Mattia E, Cecchin E,
Roncato R and Toffoli G: Pharmacogenomics of targeted agents for
personalization of colorectal cancer treatment. Int J Mol Sci.
18(pii: E1522)2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
DeStefanis RA, Kratz JD, Emmerich PB and
Deming DA: Targeted therapy in metastatic colorectal cancer:
Current standards and novel agents in review. Curr Colorectal
Cancer Rep. 15:61–69. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Wakai T, Prasoon P, Hirose Y, Shimada Y,
Ichikawa H and Nagahashi M: Next-generation sequencing-based
clinical sequencing: Toward precision medicine in solid tumors. Int
J Clin Oncol. 24:115–122. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Zhang L, Chen L, Sah S, Latham GJ, Patel
R, Song Q, Koeppen H, Tam R, Schleifman E, Mashhedi H, et al:
Profiling cancer gene mutations in clinical formalin-fixed,
paraffin-embedded colorectal tumor specimens using targeted
next-generation sequencing. Oncologist. 19:336–343. 2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Del Vecchio F, Mastroiaco V, Di Marco A,
Compagnoni C, Capece D, Zazzeroni F, Capalbo C, Alesse E and
Tessitore A: Next-generation sequencing: Recent applications to the
analysis of colorectal cancer. J Transl Med. 15(246)2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Wang Y, Liu H, Hou Y, Zhou X, Liang L,
Zhang Z, Shi H, Xu S, Hu P, Zheng Z, et al: Performance validation
of an amplicon-based targeted next-generation sequencing assay and
mutation profiling of 648 Chinese colorectal cancer patients.
Virchows Arch. 472:959–968. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Youssef O, Sarhadi V, Ehsan H, Böhling T,
Carpelan-Holmström M, Koskensalo S, Puolakkainen P, Kokkola A and
Knuutila S: Gene mutations in stool from gastric and colorectal
neoplasia patients by next-generation sequencing. World J
Gastroenterol. 23:8291–8299. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kidess E, Heirich K, Wiggin M, Vysotskaia
V, Visser BC, Marziali A, Wiedenmann B, Norton JA, Lee M, Jeffrey
SS and Poultsides GA: Mutation profiling of tumor DNA from plasma
and tumor tissue of colorectal cancer patients with a novel,
high-sensitivity multiplexed mutation detection platform.
Oncotarget. 6:2549–2561. 2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Normanno N, Cervantes A, Ciardiello F, De
Luca A and Pinto C: The liquid biopsy in the management of
colorectal cancer patients: Current applications and future
scenarios. Cancer Treat Rev. 70:1–8. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Cserni G: Nodal staging of colorectal
carcinomas and sentinel nodes. J Clin Pathol. 56:327–335.
2003.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Yang X, Zhuo M, Ye X, Bai H, Wang Z, Sun
Y, Zhao J, An T, Duan J, Wu M and Wang J: Quantification of mutant
alleles in circulating tumor DNA can predict survival in lung
cancer. Oncotarget. 7:20810–20824. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang
JJ, Xu CR, Yan HH, Chen HJ, Su J, Zhong WZ, et al: Relative
abundance of EGFR mutations predicts benefit from gefitinib
treatment for advanced non-small-cell lung cancer. J Clin Oncol.
29:3316–3321. 2011.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Jeong JH, Kim J, Hong YS, Kim D, Kim JE,
Kim SY, Kim KP, Yoon YK, Kim D, Chun SM, et al: HER2 amplification
and cetuximab efficacy in patients with metastatic colorectal
cancer harboring wild-type RAS and BRAF. Clin Colorectal Cancer.
16:e147–e152. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Lee MS, Helms TL, Feng N, Gay J, Chang QE,
Tian F, Wu JY, Toniatti C, Heffernan TP, Powis G, et al: Efficacy
of the combination of MEK and CDK4/6 inhibitors in vitro and in
vivo in KRAS mutant colorectal cancer models. Oncotarget.
7:39595–39608. 2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Stintzing S, Miller-Phillips L, Modest DP,
Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U,
Al-Batran SE, Heintges T, Kahl C, et al: Impact of BRAF and RAS
mutations on first-line efficacy of FOLFIRI plus cetuximab versus
FOLFIRI plus bevacizumab: Analysis of the FIRE-3 (AIO KRK-0306)
study. Eur J Cancer. 79:50–60. 2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Wang X, Wei Q, Gao J, Li J, Li J, Gong J,
Li Y and Shen L: Clinicopathologic features and treatment efficacy
of Chinese patients with BRAF-mutated metastatic colorectal cancer:
A retrospective observational study. Chin J Cancer.
36(81)2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Fontanges Q, De Mendonca R, Salmon I, Le
Mercier M and D'Haene N: Clinical application of targeted next
generation sequencing for colorectal cancers. Int J Mol Sci.
17(pii: E2117)2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Benson AB III, Venook AP, Cederquist L,
Chan E, Chen YJ, Cooper HS, Deming D, Engstrom PF, Enzinger PC,
Fichera A, et al: Colon cancer, version 1.2017, NCCN clinical
practice guidelines in oncology. J Natl Compr Canc Netw.
15:370–398. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Sepulveda AR, Hamilton SR, Allegra CJ,
Grody W, Cushman-Vokoun AM, Funkhouser WK, Kopetz SE, Lieu C,
Lindor NM, Minsky BD, et al: Molecular biomarkers for the
evaluation of colorectal cancer: Guideline from the American
Society for Clinical Pathology, College of American Pathologists,
Association for Molecular Pathology, and American Society of
Clinical Oncology. J Mol Diagn. 19:187–225. 2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Corcoran RB, Atreya CE, Falchook GS, Kwak
EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock
R, et al: Combined BRAF and MEK inhibition with dabrafenib and
trametinib in BRAF V600-mutant colorectal cancer. J Clin Oncol.
33:4023–4031. 2015.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Fernandes MS, Sanches JM and Seruca R:
Targeting the PI3K signalling as a therapeutic strategy in
colorectal cancer. Adv Exp Med Biol. 1110:35–53. 2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Dhillon S: Regorafenib: A review in
metastatic colorectal cancer. Drugs. 78:1133–1144. 2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Xue WS, Men SY, Liu W and Liu RH: A
meta-analysis of safety and efficacy of regorafenib for refractory
metastatic colorectal cancer. Medicine (Baltimore).
97(e12635)2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Aprile G, Macerelli M and Giuliani F:
Regorafenib for gastrointestinal malignancies: From preclinical
data to clinical results of a novel multi-target inhibitor.
BioDrugs. 27:213–224. 2013.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Krishnaswamy S, Kanteti R, Duke-Cohan JS,
Loganathan S, Liu W, Ma PC, Sattler M, Singleton PA, Ramnath N,
Innocenti F, et al: Ethnic differences and functional analysis of
MET mutations in lung cancer. Clin Cancer Res. 15:5714–5723.
2009.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Bradley CA, Salto-Tellez M, Laurent-Puig
P, Bardelli A, Rolfo C, Tabernero J, Khawaja HA, Lawler M, Johnston
PG, Van Schaeybroeck S and MErCuRIC consortium: Targeting c-MET in
gastrointestinal tumours: Rationale, opportunities and challenges.
Nat Rev Clin Oncol. 14:562–576. 2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Pietrantonio F, Oddo D, Gloghini A,
Valtorta E, Berenato R, Barault L, Caporale M, Busico A, Morano F,
Gualeni AV, et al: MET-driven resistance to dual EGFR and BRAF
blockade may be overcome by switching from EGFR to MET inhibition
in BRAF-mutated colorectal cancer. Cancer Discov. 6:963–971.
2016.PubMed/NCBI View Article : Google Scholar
|
|
34
|
DiNardo CD, Stein EM, de Botton S, Roboz
GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, Pollyea
DA, et al: Durable remissions with ivosidenib in IDH1-mutated
relapsed or refractory AML. N Engl J Med. 378:2386–2398.
2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Kloth M, Ruesseler V, Engel C, Koenig K,
Peifer M, Mariotti E, Kuenstlinger H, Florin A, Rommerscheidt-Fuss
U, Koitzsch U, et al: Activating ERBB2/HER2 mutations indicate
susceptibility to pan-HER inhibitors in Lynch and Lynch-like
colorectal cancer. Gut. 65:1296–1305. 2016.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Soussi T and Wiman KG: Shaping genetic
alterations in human cancer: The p53 mutation paradigm. Cancer
Cell. 12:303–312. 2007.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Blandino G and Di Agostino S: New
therapeutic strategies to treat human cancers expressing mutant p53
proteins. J Exp Clin Cancer Res. 37(30)2018.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Li XL, Zhou J, Chan ZL, Chooi JY, Chen ZR
and Chng WJ: PRIMA-1met (APR-246) inhibits growth of colorectal
cancer cells with different p53 status through distinct mechanisms.
Oncotarget. 6:36689–36699. 2015.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Katoh M and Katoh M: Molecular genetics
and targeted therapy of WNT-related human diseases (Review). Int J
Mol Med. 40:587–606. 2017.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Pearlman R, Frankel WL, Swanson B, Zhao W,
Yilmaz A, Miller K, Bacher J, Bigley C, Nelsen L, Goodfellow PJ, et
al: Prevalence and spectrum of germline cancer susceptibility gene
mutations among patients with early-onset colorectal cancer. JAMA
Oncol. 3:464–471. 2017.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Yurgelun MB, Kulke MH, Fuchs CS, Allen BA,
Uno H, Hornick JL, Ukaegbu CI, Brais LK, McNamara PG, Mayer RJ, et
al: Cancer susceptibility gene mutations in individuals with
colorectal cancer. J Clin Oncol. 35:1086–1095. 2017.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Kato S, Schwaederle M, Daniels GA,
Piccioni D, Kesari S, Bazhenova L, Shimabukuro K, Parker BA, Fanta
P and Kurzrock R: Cyclin-dependent kinase pathway aberrations in
diverse malignancies: Clinical and molecular characteristics. Cell
Cycle. 14:1252–1259. 2015.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Finn RS, Crown JP, Lang I, Boer K,
Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, et
al: The cyclin-dependent kinase 4/6 inhibitor palbociclib in
combination with letrozole versus letrozole alone as first-line
treatment of oestrogen receptor-positive, HER2-negative, advanced
breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study.
Lancet Oncol. 16:25–35. 2015.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Patnaik A, Rosen LS, Tolaney SM, Tolcher
AW, Goldman JW, Gandhi L, Papadopoulos KP, Beeram M, Rasco DW,
Hilton JF, et al: Efficacy and safety of abemaciclib, an inhibitor
of CDK4 and CDK6, for patients with breast cancer, non-small cell
lung cancer, and other solid tumors. Cancer Discov. 6:740–753.
2016.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Korphaisarn K, Morris VK, Overman MJ,
Fogelman DR, Kee BK, Raghav KPS, Manuel S, Shureiqi I, Wolff RA,
Eng C, et al: FBXW7 missense mutation: A novel negative prognostic
factor in metastatic colorectal adenocarcinoma. Oncotarget.
8:39268–39279. 2017.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Lorans M, Dow E, Macrae FA, Winship IM and
Buchanan DD: Update on hereditary colorectal cancer: Improving the
clinical utility of multigene panel testing. Clin Colorectal
Cancer. 17(e293-e305)2018.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Ma H, Brosens LAA, Offerhaus GJA,
Giardiello FM, de Leng WWJ and Montgomery EA: Pathology and
genetics of hereditary colorectal cancer. Pathology. 50:49–59.
2018.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Lindor NM, McMaster ML, Lindor CJ and
Greene MH; National Cancer Institute, Division of Cancer
Prevention, Community Oncology and Prevention Trials Research
Group: Concise handbook of familial cancer susceptibility
syndromes-second edition. J Natl Cancer Inst Monogr: 1-93,
2008.
|
|
49
|
Dudley JC, Lin MT, Le DT and Eshleman JR:
Microsatellite instability as a biomarker for PD-1 blockade. Clin
Cancer Res. 22:813–820. 2016.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Ryan E, Sheahan K, Creavin B, Mohan HM and
Winter DC: The current value of determining the mismatch repair
status of colorectal cancer: A rationale for routine testing. Crit
Rev Oncol Hematol. 116:38–57. 2017.PubMed/NCBI View Article : Google Scholar
|
